Shamburg News · 8-K filed Oct 29, 2026, 7:03 AM EDT

Kiora Pharmaceuticals Licenses KIO-401 from Senju for Ex-Asia Development in Eye Diseases

KPRX · KIORA PHARMACEUTICALS INC

  • Material agreement
  • Reg FD disclosure
  • Materiality: high

On October 23, 2026, Kiora Pharmaceuticals entered into an exclusive license agreement with Senju Pharmaceutical for KIO-401, a late-stage oral calpain inhibitor, covering territories outside specified Asian countries, with an effective date of October 5, 2026. Kiora agreed to pay a $3.5 million up-front payment, a low-teen-million payment upon technology transfer, up to $168.5 million in milestones, and single-digit royalties. The company announced the deal in a press release and investor presentation on October 29, 2026, and plans a Phase 3 trial in central retinal artery occlusion targeted for 2027 and a Phase 2b trial in NAION.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 7.01, 9.01, accession 0001372514-26-000088.

Written from the filing by Shamburg Markets. Figures are as reported by the company.